Sphere Fluidics rebrands to Sphere Bio

Sphere Fluidics today announced its rebranding to Sphere Bio. The name change marks a significant milestone in the Company’s development, reflecting its transition from a leading droplet-based microfluidics innovator to an established commercial provider of integrated life sciences tools and solutions.

Edwards continues M&A spree with Genesis’ TAVR tech

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Edwards Lifesciences has purchased a

August 19, 2024

Novartis, Seagen veteran David Epstein is back, leading a new cancer startup

LONDON — It hasn’t even been a year since Pfizer closed its $43 billion acquisition of Seagen — one of the biggest biopharma deals in

October 28, 2024

Filament Health Announces Authorization of Phase 2 Clinical Trial for PEX010 in the Treatment of Methamphetamine Use Disorder | Psychedelic Invest

VANCOUVER, BC, June 3, 2024 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE:7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, today announced

June 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.